| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Copaxone Slows Progression Of Disability, Reduces Relapses In MS TORONTO, ON -- March 18, 1998 – Research published in the current issue of Neurology shows that Copaxone(R) (glatiramer acetate for injection) can actually slow the progression of relapse-remitting Multiple Sclerosis (MS). The researchers found that Copaxone reduces the number of relapses and slows the progression of disability in patients with relapsing-remitting multiple sclerosis. A clinical trial that ran for nearly three years has shown that the longer patients take Copaxone(R), the better the results compared to placebo. The research, conducted at 11 medical centres in the United States, has significant implications for Canadians with multiple sclerosis. Multiple sclerosis is a chronic, often progressive disease of the central nervous system (brain, spinal cord and optic nerves), which affects 300,000 people in the United States (Approximately 10,000 people are diagnosed each year). The disease most often appears in people between the ages of 20 and 40 -- approximately 73 percent of people with multiple sclerosis are female. More information on: Copaxone.
|